Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cromoglicate for fatigue and urinary symptoms in multiple sclerosis
2023-507541-29-00Phase 2Authorised
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Clínico San Carlos
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Sodium cromoglicate with Placebo (2 arms). Primary endpoints: Modified Fatigue Impact Scale, Fatigue Severity Scale and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
sodium cromoglycate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-507541-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507541-29-00.